Loading...
NEJM Group was on hand to cover the 2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, held February 13 to 15 in San Francisco. Here, NEJM Journal Watch Oncology and Hematology Associate Editor Dr. Robert Dreicer reviews key trials in prostate cancer. Abstracts are available in the meeting proceedings.
In patients undergoing first-line treatment for metastatic castration-resistant prostate cancer, the addition of the poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitor talazoparib to enzalutamide offers a long-term survival benefit over enzalutamide alone, according to final overall survival data from the indus…